-+ 0.00%
-+ 0.00%
-+ 0.00%

Biomea Fusion Presents Preclinical Data For BMF-650 Oral Small Molecule GLP-1 At ObesityWeek In Atlanta

Benzinga·11/05/2025 12:17:56
Listen to the news

Biomea Fusion, Inc. ("Biomea," "Biomea Fusion" or the "Company") (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the presentation of two late breaking posters at ObesityWeek® 2025 in Atlanta, Georgia.

The presentations highlighted preclinical data for BMF-650, Biomea's investigational next-generation oral small molecule GLP-1 RA, and combination data for icovamenib, the Company's potential best-in-class covalent menin inhibitor product candidate, with semaglutide, an injectable GLP-1 based therapy.